Back

Reuben Kato Mutagaywa

Rheumatic heart disease (RHD) is 3rd most common cause of Heart failure after Hypertensive heart diseases and Cardiomyopathy in Tanzania (Makubi et al. Heart. 2014;100 (16): 1235-41). Pure Mitral stenosis comprised 15% in a cohort of RHD patients in a study done at Tanzania cardiac center. Patients are young and have complications like atrial fibrillation, Pulmonary hypertension, heart failure and Stroke as they present Late. Treatment includes Medical and invasive (surgical and percutaneous valvuloplasty) modalities. Registries (Okello et al. Afr Health Sci. 2015; 15(4): 1182-8) shows that 72% of patients requires invasive and 28% requires medical treatment. However, current situation 91% of patients are on medical treatment and 9% on invasive (8% surgical and 1% percutaneous valvuloplasty). Hence a need of studies to explore on the factors that can influence management strategies which might include clinical and histopathomorphological findings of this cohort of patients.

Contact

Email: reubenmutagaywa@yahoo.com

Phone: +255717921555

Keywords research

Histological findings;  Morphological findings; Echocardiographic findings; Rheumatic mitral stenosis; Percutaneous mitral valvuloplasty; Tanzania

Research topic

Clinical and histopathomorphological findings of rheumatic mitral valve stenosis in Tanzanian patients: Implications for surgical and non-surgical treatment outcomes

Type of research

Clinical research (cardiovascular)

Collaborations / partnerships

 Muhimbili University College of Health and Allied Sciences (MUHAS) and UMC Utrecht Global Health Support Program

Pure profile

Reuben Mutagaywa

Thank you for your review!

Has this information helped you?
Please tell us why, so that we can improve our website.

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not